SHANGHAI, November 6, 2022 /PRNewswire/ — Asieris Pharmaceuticals, a global biopharmaceutical company focused on the discovery and development of innovative medicines to treat genitourinary tumors and other serious diseases, announced that Hexvix®a drug used to diagnose bladder cancer, has completed the first patient dose in a phase III bridge study.
The study is a prospective, self-controlled, multi-center, phase Ⅲ study designed to evaluate the additional detection rate and safety of Hexvix® and blue light cystoscopy (BLC) versus white light cystoscopy in patients with non-muscle invasive bladder cancer (NMIBC) (CIS, Ta, T1).
This study is led by Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences. Professor Li Hanzhong, head of the surgical department at Peking Union Medical College Hospital, will serve as the principal investigator, leading a team of top experts in the field of bladder cancer China to conduct this study. The Company plans to submit a new drug application to the NMPA in the future pending clinical trial progress and meaningful data.
in the January 2021Asieris entered into a licensing agreement with Photocure ASA (Photocure, OSE:PHO), a bladder cancer company based in Oslo, Norwayto obtain Hexvix’s exclusive registration and marketing rights® on the mainland China and Taiwan.
in the December 2021Hexvix® was awarded as part of the Boao Lecheng International Medical Tourism Pilot…
